| name | endo-fha-fertility-pulsatile-gnrh-first-line |
| description | This skill recommends initiating fertility treatment with pulsatile GnRH as the first-line approach to induce ovulation in women with functional hypothalamic amenorrhea (FHA) who desire pregnancy, followed by gonadotropin therapy if GnRH is unavailable. Use when a clinician states, 'She wants to conceive—let’s start with pulsatile GnRH.' Triggers include language like 'First try pulsatile GnRH for ovulation' or 'Use GnRH pump before gonadotropins'. |
First-line pulsatile gonadotropin-releasing hormone for ovulation induction in FHA seeking conception
STEP 1 — Gather Information
Confirm FHA diagnosis after exclusion of organic causes (pregnancy, thyroid, prolactin, anatomic pathology). Obtain fertility workup (semen analysis, tubal patency, ovarian reserve). Document desire to conceive, baseline LH/FSH/E2, BMI, and contraceptive use. If pregnancy test negative, FHA established, and patient seeks pregnancy, proceed to next step.
STEP 2 — Rule In / Rule Out
Rule in: FHA with infertility, BMI ≥18.5 kg/m2, no pregnancy, and patient actively seeking conception. Rule out: pregnancy, BMI <18.5, untreated thyroid/prolactin disorders, or contraindications to ovulation induction. If ruled in, advance to classification; otherwise address underlying issues before fertility treatment.
STEP 3 — Classify or Stratify
Determine availability of pulsatile GnRH therapy. If GnRH pump/protocol accessible, classify as GnRH-first pathway. If GnRH unavailable (e.g., not licensed in region), classify as gonadotropin-first pathway.
STEP 4 — Decide
If GnRH-first pathway: initiate pulsatile GnRH via subcutaneous pump (e.g., 5–10 µg every 90–120 minutes, titrated to ovulation). If gonadotropin-first pathway: start low-dose gonadotropins with close monitoring for ovarian response and multiple gestation.
Clinical Guardrails / Mimics / Pitfalls
Do not start ovulation induction without confirming pregnancy exclusion and adequate BMI (≥18.5). Avoid GnRH if uncontrolled hypothyroidism or hyperprolactinemia. Exercise caution with gonadotropins due to risk of ovarian hyperstimulation syndrome, multifollicular development, and preterm labor; monitor estradiol and follicular growth. Remember GnRH is not commercially available in the United States.
Concrete Clinical Example
A 28‑year‑old woman with 6 months of amenorrhea, BMI 19, normal fertility workup, and desire to conceive is diagnosed with FHA. After negative pregnancy test, she begins pulsatile GnRH via pump at 7.5 µg every 90 minutes. Ovulation occurs after 10 days, and she conceives on the third cycle.
Source: Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, doi:10.1210/jc.2017-00131
